The KV11.1 activator NS1643 can substantially reduce the metastatic spread of triple-negative breast cancers by inhibiting cell motility, counteracting cancer cell stemness, and reprogramming the epithelial-mesenchymal transition through weakening of WNT/β-Catenin signaling. This evidence concerns the gene KCNH2 and cancer.